RU2014143213A - Соединения ингибитора тирозинкиназы и их применение - Google Patents
Соединения ингибитора тирозинкиназы и их применение Download PDFInfo
- Publication number
- RU2014143213A RU2014143213A RU2014143213A RU2014143213A RU2014143213A RU 2014143213 A RU2014143213 A RU 2014143213A RU 2014143213 A RU2014143213 A RU 2014143213A RU 2014143213 A RU2014143213 A RU 2014143213A RU 2014143213 A RU2014143213 A RU 2014143213A
- Authority
- RU
- Russia
- Prior art keywords
- tyrosine kinase
- met
- fgfr
- inhibitor
- pharmaceutically acceptable
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims abstract 14
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims abstract 14
- -1 Tyrosine kinase inhibitor compounds Chemical class 0.000 title claims abstract 5
- 108091008794 FGF receptors Proteins 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 16
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract 13
- 239000000651 prodrug Substances 0.000 claims abstract 12
- 229940002612 prodrug Drugs 0.000 claims abstract 12
- 229940122661 MET tyrosine kinase inhibitor Drugs 0.000 claims abstract 6
- 239000003112 inhibitor Substances 0.000 claims abstract 5
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical group C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims abstract 4
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims abstract 4
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims abstract 2
- 230000009916 joint effect Effects 0.000 claims abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 18
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 4
- 229940000425 combination drug Drugs 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| US61/619,502 | 2012-04-03 | ||
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014143213A true RU2014143213A (ru) | 2016-05-27 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014143213A RU2014143213A (ru) | 2012-04-03 | 2013-04-01 | Соединения ингибитора тирозинкиназы и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (enExample) |
| EP (1) | EP2833917A1 (enExample) |
| JP (1) | JP2015512447A (enExample) |
| KR (1) | KR20140146086A (enExample) |
| CN (1) | CN104244982A (enExample) |
| AU (1) | AU2013243737B2 (enExample) |
| CA (1) | CA2866321A1 (enExample) |
| IN (1) | IN2014DN07410A (enExample) |
| MX (1) | MX2014011987A (enExample) |
| RU (1) | RU2014143213A (enExample) |
| WO (1) | WO2013151913A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| US10195208B2 (en) * | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
| CN114984013A (zh) | 2015-03-25 | 2022-09-02 | 国立癌症研究中心 | 胆管癌治疗剂 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2016374441B2 (en) | 2015-12-17 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| RS55630B1 (sr) | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| GEP20125658B (en) * | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| CA2683559C (en) * | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| BRPI0911491A2 (pt) * | 2008-04-29 | 2016-01-05 | Novartis Ag | métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos. |
| WO2009140549A1 (en) * | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| BR112012003262A8 (pt) * | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
-
2013
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en not_active Ceased
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Withdrawn
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2866321A1 (en) | 2013-10-10 |
| IN2014DN07410A (enExample) | 2015-04-24 |
| KR20140146086A (ko) | 2014-12-24 |
| US20150051210A1 (en) | 2015-02-19 |
| JP2015512447A (ja) | 2015-04-27 |
| MX2014011987A (es) | 2014-11-10 |
| EP2833917A1 (en) | 2015-02-11 |
| CN104244982A (zh) | 2014-12-24 |
| WO2013151913A1 (en) | 2013-10-10 |
| AU2013243737B2 (en) | 2016-06-30 |
| AU2013243737A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7503380B2 (ja) | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2014505735A5 (enExample) | ||
| KR20250065935A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| WO2015048662A3 (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| JP2012236857A5 (enExample) | ||
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| FI4406594T3 (fi) | Kilpirauhashormonin analogeja | |
| RU2016129811A (ru) | Фармацевтические комбинации | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| PL2004653T3 (pl) | 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy | |
| RU2015137596A (ru) | Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| Awada et al. | Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors | |
| RU2014129508A (ru) | Новая комбинация | |
| EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы | |
| KR20220059519A (ko) | 키나제 억제제에 의한 한선염의 치료 | |
| TW201006823A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170808 |